Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Consider supplements: Explore non-prescription options like GLP-1 Daily Support to help manage the journey
Need help with your workouts
Zepbound (tirzepatide), when prescribed properly, can be an effective treatment for adult patients struggling with a chronic disease like obesity or being overweight
However, it is risky
Studies show that higher levels are associated with smaller fat cell size and healthier fat distribution patterns
US$ 25.53
US$ 26.42
US$ 27.01
US$ 21.93
US$ 26.80
US$ 24.51
US$ 25.04
US$ 22.73
US$ 23.82
US$ 24.80
US$ 29.95
US$ 20.87
US$ 26.97
